<DOC>
	<DOCNO>NCT01278433</DOCNO>
	<brief_summary>The aim study collect post marketing safety data IMOVAX Polio vaccine China . Objective : To describe serious adverse event 30 day dose IMOVAX Polio™ administer 2 , 3 , 4 month age among infant live study city China .</brief_summary>
	<brief_title>A Safety Study IMOVAX Polio Vaccine Selected Cities China</brief_title>
	<detailed_description>Each study participant receive IMOVAX Polio™ injection 2 , 3 4 month age ( total 3 dos ) follow 30 day vaccination .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject 2 month age old ( 6089days ) receive first dose polio vaccine . Subject 's parent /legal representative show willingness complete 3 primary dos fully use IMOVAX Polio accord schedule . one injection 2 , 3 , 4 month old respectively ; Informed consent form obtain subject 's parent/legal representative . Subject plan live select study site least three month inclusion . Subject history serious illness ( i.e. , hypersensitivity , seizure , convulsion , encephalopathy disease , etc . ) Acute medical illness without fever within last 72 hour . Vaccination plan 4 week follow trial vaccination ( except Diphtheria , Tetanus , Pertussis ( DTP ) , Hib vaccine Pneumo vaccine ) Participation another clinical trial time . Contraindications vaccination accord IMOVAX Polio™ leaflet . Subject plan leave study site least three month inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Polio</keyword>
	<keyword>Poliovirus</keyword>
	<keyword>IMOVAX Polio™</keyword>
</DOC>